SCHEDULE: BlackRock Discloses 5.1% Stake in LENZ THERAPEUTICS
Beneficial Ownership Disclosure
BlackRock, Inc. has reported a 5.1% beneficial ownership stake in LENZ THERAPEUTICS, INC. as of September 30, 2025, through a Schedule 13G filing.
Summary
- BlackRock, Inc. beneficially owns 1,442,864 shares of LENZ THERAPEUTICS, INC. Common Stock.
- This ownership represents 5.1% of the total outstanding shares of the class.
- BlackRock holds sole voting power over 1,413,274 shares and sole dispositive power over 1,442,864 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of LENZ THERAPEUTICS, INC.
- BlackRock, Inc. is classified as a parent holding company (HC) for this filing.
- Several BlackRock subsidiaries are identified as potentially holding the reported securities, with at least one entity beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a routine disclosure of passive institutional ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It simply reports a factual ownership position.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding LENZ THERAPEUTICS, INC.'s future performance or BlackRock's future investment intentions beyond the passive nature of the stake.
Management Comments
- Securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
BlackRock, as one of the world's largest asset managers, routinely files Schedule 13G reports to disclose passive ownership stakes exceeding 5% in publicly traded companies. This filing indicates BlackRock's investment in LENZ THERAPEUTICS, INC. as part of its diversified portfolio management, reflecting institutional interest in the company.
Stakeholder Impact
- Shareholders of LENZ THERAPEUTICS, INC. may perceive BlackRock's significant stake as a validation of the company's investment potential by a major institutional investor.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Power of Attorney executed by BlackRock, Inc. |
| 09/30/2025 | Date of event which requires the filing of this statement (beneficial ownership threshold met). |
| 10/17/2025 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, LENZ THERAPEUTICS, Schedule 13G, Institutional Ownership, Common Stock, Investment, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.